<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rpmj</journal-id><journal-title-group><journal-title xml:lang="ru">Research'n Practical Medicine Journal</journal-title><trans-title-group xml:lang="en"><trans-title>Research and Practical Medicine Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2410-1893</issn><publisher><publisher-name>"QUASAR", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17709/2410-1893-2022-9-2-4</article-id><article-id custom-type="elpub" pub-id-type="custom">rpmj-743</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи. Онкология, лучевая терапия</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Articles. Оncology</subject></subj-group></article-categories><title-group><article-title>Исследование противоопухолевой активности 2-хинолин-2-ил-производного 1,3-трополона в эксперименте</article-title><trans-title-group xml:lang="en"><trans-title>Study of biological activity of 2-quinoline-2-yl-derivative 1,3-tropolone in experiment</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3036-6199</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лукбанова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lukbanova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лукбанова Екатерина Алексеевна – научный сотрудник. SPIN: 4078-4200, AuthorID: 837861</p><p>344037, г. Ростов-на-Дону, ул. 14-я линия, д. 63</p></bio><bio xml:lang="en"><p>Ekaterina A. Lukbanova – researcher. SPIN: 4078-4200, AuthorID: 837861</p><p>63 14 line str., Rostov-on-Don 344037</p></bio><email xlink:type="simple">katya.samarskaja@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3561-098X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дженкова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dzhenkova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дженкова Елена Алексеевна – д.б.н., доцент, ученый секретарь. SPIN: 6206-6222, AuthorID: 697354, ResearcherID: K-9622-2014, Scopus Author ID: 6507889745</p><p>г. Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Elena A. Dzhenkova – Dr. Sci. (Biol.), associate professor, scientific secretary. SPIN: 6206-6222, AuthorID: 697354, ResearcherID: K-9622-2014, Scopus Author ID: 6507889745</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">info@cancersp.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0676-0871</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гончарова</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Goncharova</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гончарова Анна Сергеевна – к.б.н., заведующая лабораторией. SPIN: 7512-2039, AuthorID: 553424</p><p>г. Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Anna S. Goncharova – Cand. Sci. (Biol.), head of laboratory. SPIN: 7512-2039, AuthorID: 553424</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">fateyeva_a_s@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1397-837X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максимов</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Maksimov</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Максимов Алексей Юрьевич – д.м.н., профессор, заместитель генерального директора по перспективным научным разработкам. SPIN: 7322-5589, AuthorID: 710705, Scopus Author ID: 56579049500</p><p>г. Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Alexei Yu. Maksimov – Dr. Sci. (Med.), professor, deputy general director for advanced scientific research of the department of oncourology. SPIN: 7322-5589, AuthorID: 710705, Scopus Author ID: 56579049500</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">rnioi@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7553-6550</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Комарова</surname><given-names>Е. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Komarova</surname><given-names>E. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Комарова Екатерина Федоровна – профессор РАН, д.б.н., ведущий научный сотрудник. SPIN: 1094-3139, AuthorID: 348709, ResearcherID: T-4520-2019</p><p>г. Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Ekaterina F. Кomarova – professor of Russian Academy of Sciences, Dr. Sci. (Biol.), professor, senior research fellow. SPIN: 1094-3139, AuthorID: 348709, ResearcherID: T-4520-2019</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">katitako@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6096-503X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Минкин</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Minkin</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Минкин Владимир Исаакович – академик РАН, д.х.н., научный руководитель. SPIN: 1226-7767, AuthorID: 45587</p><p>г. Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Vladimir I. Minkin – academician of the Russian Academy of Sciences, Dr. Sci. (Chem.), scientific supervisor. SPIN: 1226-7767, AuthorID: 45587</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">minkin@ipoc.sfedu.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3180-1762</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саяпин</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sayapin</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Саяпин Юрий Анатольевич – к.х.н., руководитель лаборатории. SPIN: 4877-3959, AuthorID: 121929</p><p>г. Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Yury A. Sayapin – Cand. Sci. (Chem.), head of laboratory. SPIN: 4877-3959, AuthorID: 121929</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">sayapinscience@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7593-1334</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гусаков</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gusakov</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гусаков Евгений Александрович – научный сотрудник. SPIN: 1690-9488, AuthorID: 789745</p><p>г. Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Evgeny A. Gusakov – researcher, research institute of physical and organic chemistry. SPIN: 1690-9488, AuthorID: 789745</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">gusakovevgeniy@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3436-1325</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Курбанова</surname><given-names>Л. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Kurbanova</surname><given-names>L. Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Курбанова Луиза Зулкаидовна – младший научный сотрудник. SPIN: 9060-4853, AuthorID: 1020533</p><p>г. Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Luiza Z. Kurbanova – junior researcher. SPIN: 9060-4853, AuthorID: 1020533</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">luizacurbanowa@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9337-5535</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Киблицкая</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kiblitskaya</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Киблицкая Александра Андреевна – научный сотрудник. SPIN: 2437-4102, AuthorID: 610872</p><p>г. Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Alexandra A. Kiblitskaya – researcher. SPIN: 2437-4102, AuthorID: 610872</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">kibaleand@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0088-2990</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Заикина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zaikina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Заикина Екатерина Владиславовна – младший научный сотрудник. SPIN: 4000-4369, AuthorID: 1045258</p><p>г. Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Ekaterina V. Zaikina – junior researcher. SPIN: 4000-4369, AuthorID: 1045258</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">katherine_bio@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8734-9210</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Миндарь</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mindar</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Миндарь Мария Вадимовна – младший научный сотрудник. SPIN: 5148-0830, AuthorID: 1032029</p><p>г. Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Maria V. Mindar – junior researcher. SPIN: 5148-0830, AuthorID: 1032029</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">m.v.mindar@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2302-3542</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волошин</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Voloshin</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Волошин Марк Витальевич – врач-онколог. SPIN: 6122-4084, AuthorID: 969003</p><p>г. Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Mark V. Voloshin – oncologist. SPIN: 6122-4084, AuthorID: 969003</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">markvoloshin95@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8857-9691</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шапошников</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shaposhnikov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шапошников Александр Васильевич – д.м.н., профессор, главный научный сотрудник торакоабдоминального отдела. SPIN: 8756-9438, AuthorID: 712823</p><p>г. Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Alexander V. Shaposhnikov – Dr. Sci. (Med.), professor, chief researcher of the thoracoabdominal department. SPIN: 8756-9438, AuthorID: 712823</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">rnioi@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6605-3573</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лысенко</surname><given-names>И. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Lysenko</surname><given-names>I. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лысенко Ирина Борисовна – д.м.н., профессор, заведующая отделением онкогематологии. SPIN: 9510-3504, AuthorID: 794669</p><p>г. Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Irina B. Lysenko – Dr. Sci. (Med.), professor, head of the department of oncohematology. SPIN: 9510-3504, AuthorID: 794669</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">iralyss@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6323-4862</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Николаева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikolaeva</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Николаева Надежда Владимировна – д.м.н., врач-онкогематолог. SPIN: 4295-5920, AuthorID: 733869</p><p>г. Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Nadezhda V. Nikolaeva – Dr. Sci. (Med.), oncohematologist. SPIN: 4295-5920, AuthorID: 733869</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">nadya.nikolaeva.74@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НМИЦ онкологии</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Centre for Oncology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>НИИ ФОХ Южный Федеральный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Physical and Organic Chemistry of the Southern Federal University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Южный научный центр РАН</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Southern Scientific Center of the Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>24</day><month>03</month><year>2022</year></pub-date><volume>9</volume><issue>2</issue><fpage>50</fpage><lpage>64</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лукбанова Е.А., Дженкова Е.А., Гончарова А.С., Максимов А.Ю., Комарова Е.Ф., Минкин В.И., Саяпин Ю.А., Гусаков Е.А., Курбанова Л.З., Киблицкая А.А., Заикина Е.В., Миндарь М.В., Волошин М.В., Шапошников А.В., Лысенко И.Б., Николаева Н.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Лукбанова Е.А., Дженкова Е.А., Гончарова А.С., Максимов А.Ю., Комарова Е.Ф., Минкин В.И., Саяпин Ю.А., Гусаков Е.А., Курбанова Л.З., Киблицкая А.А., Заикина Е.В., Миндарь М.В., Волошин М.В., Шапошников А.В., Лысенко И.Б., Николаева Н.В.</copyright-holder><copyright-holder xml:lang="en">Lukbanova E.A., Dzhenkova E.A., Goncharova A.S., Maksimov A.Y., Komarova E.F., Minkin V.I., Sayapin Y.A., Gusakov E.A., Kurbanova L.Z., Kiblitskaya A.A., Zaikina E.V., Mindar M.V., Voloshin M.V., Shaposhnikov A.V., Lysenko I.B., Nikolaeva N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpmj.ru/rpmj/article/view/743">https://www.rpmj.ru/rpmj/article/view/743</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Изучение противоопухолевого эффекта 2‑(6,8‑диметил‑5‑нитро‑4‑хлорхинолин‑2‑ил)‑5,6,7‑трихлор‑1,3‑трополона в отношении подкожных PDX‑моделей рака легкого человека.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Исследуемый трополон синтезирован методом расширения о‑хинонового цикла. Оценку его токсических эффектов проводили на основании данных о выживаемости, отклонениях в состоянии здоровья самок мышей Balb/c Nude. Исследование противоопухолевой активности трополона проводилось на подкожных PDX‑моделях (PatientDerived Xenograft) плоскоклеточного рака легкого человека на мышах линии Balb/c Nude. При этом учитывали средний объем опухолевых узлов и показатель торможения роста опухоли – ТРО (%). Помимо этого, проводили биохимический анализ крови мышей‑реципиентов и гистологическое исследование опухолевого материала.</p></sec><sec><title>Результаты</title><p>Результаты. При проведении исследования токсических эффектов трополона не было выявлено летальной дозы. Наибольшее торможение роста опухоли – 73,5 и 74,4 % для самок и самцов соответственно – наблюдалось на 36‑е сутки эксперимента в 5 группе, которой вводили 2,75 мг/г трополона. В данной группе средние объемы у самок достигали максимального значения – 431,3 ± 1,1 мм3 на 33‑е сутки эксперимента, у самцов – 428,9 ± 1,7 мм3 на 30‑й день, после чего уменьшались. Проведенные биохимический анализ крови и гистологическое исследование опухолевой ткани мышей‑реципиентов отражают выраженность противоопухолевого эффекта от дозы исследуемого трополона.</p></sec><sec><title>Заключение</title><p>Заключение. Таким образом, в ходе исследований была продемонстрирована противоопухолевая активность 2‑(6,8‑диметил‑5‑нитро‑4‑хлорхинолин‑2‑ил)‑5,6,7‑трихлор‑1,3‑трополона в отношении подкожных PDX‑моделей НМРЛ человека. Выявленные зависимости могут быть использованы в дальнейшем для поиска эффективных режимов применения данного соединения в клинической практике.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose of the study</title><p>Purpose of the study. Was to reveal the antitumor effect of 2‑(6,8‑dimethyl‑5‑nitro‑4‑chloroquinoline‑2‑yl)‑5,6,7‑trichloro‑1,3‑tropolone in subcutaneous PDX models of human lung cancer.</p></sec><sec><title>Material and methods</title><p>Material and methods. The studied tropolone was synthesized using a method of expanding the o‑quinone cycle. Assess to it’s toxic effects was given by the survival and changes in the health status of female Balb/c Nude mice. Antitumor tropolone effects were studied in subcutaneous patient‑derived xenograft (PDX) models of human squamous cell lung cancer in Balb/c Nude mice. The average volumes of tumor nodes and tumor growth inhibition (TGI %) rate were taken into account. Biochemical blood tests and histological analysis of the tumor material were performed in recipient mice.</p></sec><sec><title>Results</title><p>Results. An analysis of acute tropolone toxic effects did not reveal the lethal dose. The maximal TGI was observed on day 36 of the experiment in group 5 which have received 2.75 mg/g tropolone and accounted 73.5 % for females and 74.4 % for males. The average tumor volumes in females of this group were 431.3 ± 1,1 mm3 on day 33 of the experiment, in males – 428.9 ± 1,7 mm3 on day 30, and then the tumor volumes declined. The biochemical analysis of blood and histological examination of the tumor tissue of recipient mice reflect the severity of the antitumor effect on the dose of the studied tropolone.</p></sec><sec><title>Conclusion</title><p>Conclusion. The research demonstrated the antitumor activity of 2‑(6,8‑dimethyl‑5‑nitro‑4‑chloroquinoline‑2‑yl)‑5,6,7‑trichloro‑1,3‑tropolone against subcutaneous PDX models of human NSCLC. The revealed tendencies can be used to search for effective modes of the compound application in clinical practice.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>трополоны</kwd><kwd>противоопухолевая активность</kwd><kwd>мыши линии Balb/c Nude</kwd><kwd>ксенографт</kwd><kwd>дозозависимые эффекты</kwd><kwd>токсическое влияние</kwd><kwd>немелкоклеточный рак легкого (НМРЛ)</kwd></kwd-group><kwd-group xml:lang="en"><kwd>tropolones</kwd><kwd>antitumor activity</kwd><kwd>Balb/c Nude mice</kwd><kwd>xenograft</kwd><kwd>dose dependent effects</kwd><kwd>toxic effect</kwd><kwd>non-small-cell lung carcinoma (NSCLC)</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Синтез исследуемого соединения осуществляли в рамках реализации Государственного задания ЮНЦ РАН № 01201354239 при финансовой поддержке Министерства науки и высшего образования Российской Федерации (Государственное задание в области научной деятельности, проект № 0852-2020-0031). Исследования in vivo проводили в рамках государственного задания № 121031100253-3 «Изучение противоопухолевой активности фармакологических субстанций in vivo и in vitro».</funding-statement><funding-statement xml:lang="en">The studied compound was synthesized as part of implementation of the SSC RAS State task No. 01201354239, with financial support of the Ministry of Science and Higher Education of the Russian Federation (State task in science, project No. 0852-2020-0031). Studies in vivo were performed as part of the State task No. 121031100253-3 “Study of antitumor activity of pharmacological substances in vivo and in vitro”.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Кит О. И., Франциянц Е. М., Меньшенина А. П., Моисеенко Т. И., Ушакова Н. Д., Попова Н. Н. и др. Роль плазмофереза и ксенонтерапии в коррекции острых последствий хирургической менопаузы у больных раком шейки матки. Политематический сетевой электронный научный журнал Кубанского государственного аграрного университета. 2016;(117):472–486.</mixed-citation><mixed-citation xml:lang="en">Kit OI, Frantsiyants EM, Menshenina AP, Moiseenko TI, Ushakova ND, Popova NN, et al. Role of plasmapheresis and xenon therapy in correcting the acute effects of surgical menopause in patients with cervical cancer. Polythematic online electronic scientific journal of the Kuban State Agrarian University. 2016;(117):472–486. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. https://doi.org/10.3322/caac.21492</mixed-citation><mixed-citation xml:lang="en">Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. https://doi.org/10.3322/caac.21492</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">National Cancer Institute. Cancer Stat Facts: Lung and Bronchus Cancer. 2019. Доступно по: https://seer.cancer.gov/statfacts/html/lungb.html, Дата обращения: 23.03.2022.</mixed-citation><mixed-citation xml:lang="en">National Cancer Institute. Cancer Stat Facts: Lung and Bronchus Cancer. 2019. Available at: https://seer.cancer.gov/statfacts/html/lungb.html, Accessed: 23.03.2022.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gonzalez‑Rajal A, Hastings JF, Watkins DN, Croucher DR, Burgess A. Breathing New Life into the Mechanisms of Platinum Resistance in Lung Adenocarcinoma. Front Cell Dev Biol. 2020;8:305. https://doi.org/10.3389/fcell.2020.00305</mixed-citation><mixed-citation xml:lang="en">Gonzalez‑Rajal A, Hastings JF, Watkins DN, Croucher DR, Burgess A. Breathing New Life into the Mechanisms of Platinum Resistance in Lung Adenocarcinoma. Front Cell Dev Biol. 2020;8:305. https://doi.org/10.3389/fcell.2020.00305</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Бурнашева Е. В., Шатохин Ю. В., Снежко И. В., Мацуга А. А. Поражение почек при противоопухолевой терапии. Нефрология. 2018;22(5):17–24. https://doi.org/10.24884/1561‑6274‑2018‑22‑5‑17‑24</mixed-citation><mixed-citation xml:lang="en">Burnasheva EV, Shatokhin YuV, Snezhko IV, Matsuga AA. Kidney injury in cancer therapy. Nephrology (Saint‑Petersburg). 2018;22(5):17–24. (In Russ.). https://doi.org/10.24884/1561‑6274‑2018‑22‑5‑17‑24</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kit OI, Shikhlyarova AI, Maryanovskaya GY, Barsukova LP, Kuzmenko TS, Zhukova GV, et al. Theory of health: successful translation into the real life. General biological prerequisites. Cardiometry. 2015;(7):11–17. https://doi.org/10.12710/cardiometry.2015.7.1117</mixed-citation><mixed-citation xml:lang="en">Kit OI, Shikhlyarova AI, Maryanovskaya GY, Barsukova LP, Kuzmenko TS, Zhukova GV, et al. Theory of health: successful translation into the real life. General biological prerequisites. Cardiometry. 2015;(7):11–17. https://doi.org/10.12710/cardiometry.2015.7.1117</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Haney SL, Allen C, Varney ML, Dykstra KM, Falcone ER, Colligan SH, et al. Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells. Oncotarget. 2017 Sep 29;8(44):76085–76098. https://doi.org/10.18632/oncotarget.18543</mixed-citation><mixed-citation xml:lang="en">Haney SL, Allen C, Varney ML, Dykstra KM, Falcone ER, Colligan SH, et al. Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells. Oncotarget. 2017 Sep 29;8(44):76085–76098. https://doi.org/10.18632/oncotarget.18543</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang G, He J, Ye X, Zhu J, Hu X, Shen M, et al. β‑Thujaplicin induces autophagic cell death, apoptosis, and cell cycle arrest through ROS‑mediated Akt and p38/ERK MAPK signaling in human hepatocellular carcinoma. Cell Death Dis. 2019 Mar 15;10(4):255. https://doi.org/10.1038/s41419‑019‑1492‑6</mixed-citation><mixed-citation xml:lang="en">Zhang G, He J, Ye X, Zhu J, Hu X, Shen M, et al. β‑Thujaplicin induces autophagic cell death, apoptosis, and cell cycle arrest through ROS‑mediated Akt and p38/ERK MAPK signaling in human hepatocellular carcinoma. Cell Death Dis. 2019 Mar 15;10(4):255. https://doi.org/10.1038/s41419‑019‑1492‑6</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Maldonado EN, Patnaik J, Mullins MR, Lemasters JJ. Free tubulin modulates mitochondrial membrane potential in cancer cells. Cancer Res. 2010 Dec 15;70(24):10192–10201. https://doi.org/10.1158/0008‑5472.CAN‑10‑2429</mixed-citation><mixed-citation xml:lang="en">Maldonado EN, Patnaik J, Mullins MR, Lemasters JJ. Free tubulin modulates mitochondrial membrane potential in cancer cells. Cancer Res. 2010 Dec 15;70(24):10192–10201. https://doi.org/10.1158/0008‑5472.CAN‑10‑2429</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kurek J, Kwaśniewska‑Sip P, Myszkowski K, Cofta G, Barczyński P, Murias M, et al. Antifungal, anticancer, and docking studies of colchiceine complexes with monovalent metal cation salts. Chem Biol Drug Des. 2019 Sep;94(5):1930–1943. https://doi.org/10.1111/cbdd.13583</mixed-citation><mixed-citation xml:lang="en">Kurek J, Kwaśniewska‑Sip P, Myszkowski K, Cofta G, Barczyński P, Murias M, et al. Antifungal, anticancer, and docking studies of colchiceine complexes with monovalent metal cation salts. Chem Biol Drug Des. 2019 Sep;94(5):1930–1943. https://doi.org/10.1111/cbdd.13583</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ido Y, Muto N, Inada A, Kohroki J, Mano M, Odani T, et al. Induction of apoptosis by hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is mediated through the activation of caspase‑3. Cell Prolif. 1999 Feb;32(1):63–73. https://doi.org/10.1046/j.1365‑2184.1999.3210063.x</mixed-citation><mixed-citation xml:lang="en">Ido Y, Muto N, Inada A, Kohroki J, Mano M, Odani T, et al. Induction of apoptosis by hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is mediated through the activation of caspase‑3. Cell Prolif. 1999 Feb;32(1):63–73. https://doi.org/10.1046/j.1365‑2184.1999.3210063.x</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang G, He J, Ye X, Zhu J, Hu X, Shen M, et al. β‑Thujaplicin induces autophagic cell death, apoptosis, and cell cycle arrest through ROS‑mediated Akt and p38/ERK MAPK signaling in human hepatocellular carcinoma. Cell Death Dis. 2019 Mar 15;10(4):255. https://doi.org/10.1038/s41419‑019‑1492‑6</mixed-citation><mixed-citation xml:lang="en">Zhang G, He J, Ye X, Zhu J, Hu X, Shen M, et al. β‑Thujaplicin induces autophagic cell death, apoptosis, and cell cycle arrest through ROS‑mediated Akt and p38/ERK MAPK signaling in human hepatocellular carcinoma. Cell Death Dis. 2019 Mar 15;10(4):255. https://doi.org/10.1038/s41419‑019‑1492‑6</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Патент РФ. RU 2741311 C1. Заявка № 2020123736 от 17.07.20 г. Минкин В. И., Кит О. И., Гончарова А. С., Лукбанова Е. А., Саяпин Ю. А., Гусаков Е. А. и др. Средство, обладающее цитотоксической активностью в отношении культуры клеток немелкоклеточного рака легких А 549. Доступно по: https://patenton.ru/patent/RU2741311C1.pdf, Дата обращения: 23.03.2022.</mixed-citation><mixed-citation xml:lang="en">Patent of the Russian Federation. RU 2741311 C1. Application No. 2020123736 dated 17.07.20 Minkin VI, Kit OI, Goncharova AS, Lukyanova EA, Sayapin YuA, Gusakov EA., et al. A drug with cytotoxic activity against cell culture of non‑small cell lung cancer A 549. Available at: https://patenton.ru/patent/RU2741311C1.pdf, Accessed: 23.03.2022. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Li L‑H, Wu P, Lee J‑Y, Li P‑R, Hsieh W‑Y, Ho C‑C, et al. Hinokitiol induces DNA damage and autophagy followed by cell cycle arrest and senescence in gefitinib‑resistant lung adenocarcinoma cells. PLoS One. 2014;9(8):e104203. https://doi.org/10.1371/journal.pone.0104203</mixed-citation><mixed-citation xml:lang="en">Li L‑H, Wu P, Lee J‑Y, Li P‑R, Hsieh W‑Y, Ho C‑C, et al. Hinokitiol induces DNA damage and autophagy followed by cell cycle arrest and senescence in gefitinib‑resistant lung adenocarcinoma cells. PLoS One. 2014;9(8):e104203. https://doi.org/10.1371/journal.pone.0104203</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Патент RU № 2712916, опубл. 03.02.2020, Бюл. № 4. Колесников Е. Н., Лукбанова Е. А., Ванжа Л. В., Максимов А. Ю., Кит С. О., Гончарова А. С. и др. Способ проведения наркоза у мышей Balb/c Nude при оперативных вмешательствах. Доступно по: https://patenton.ru/patent/RU2712916C1.pdf, Дата обращения: 23.03.2022.</mixed-citation><mixed-citation xml:lang="en">Patent RU No. 2712916, publ. 03.02.2020, Byul. No. 4. Kolesnikov EN, Lukyanova EA, Vanzha LV, Maksimov AYu, Kit SO, Goncharova AS, et al. The method of anesthesia in Balb/c Nude mice during surgical interventions. Available at: https://patenton.ru/patent/RU2712916C1.pdf, Accessed: 23.03.2022. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Трещалина Е. М., Жукова О. С., Герасимова Г. К., Андронова Н. В., Гарин А. М. Методические указания по изучению противоопухолевой активности фармакологических веществ. В кн.: Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. Под ред. Хабриева Р. У. М: Медицина, 2005, 637–651 с.</mixed-citation><mixed-citation xml:lang="en">Treshchalina EM, Zhukova OS, Gerasimova GK, Andronova NV, Garin AM. Methodological guidelines for the study of antitumor activity of pharmacological substances. In: Guidelines for the experimental (preclinical) study of new pharmacological substances. Ed. by Khabrieva RU. Moscow: Medicine, 2005, 637–651 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Чибуновский В. А. Интерпретация результатов клинико‑биохимических лабораторных исследований. Алматы, 1998.</mixed-citation><mixed-citation xml:lang="en">Chibunovsky VA. Interpretation of the results of clinical and biochemical laboratory studies. Almaty, 1998.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang G, He J, Ye X, Zhu J, Hu X, Shen M, et al. β‑Thujaplicin induces autophagic cell death, apoptosis, and cell cycle arrest through ROS‑mediated Akt and p38/ERK MAPK signaling in human hepatocellular carcinoma. Cell Death Dis. 2019 Mar 15;10(4):255. https://doi.org/10.1038/s41419‑019‑1492‑6</mixed-citation><mixed-citation xml:lang="en">Zhang G, He J, Ye X, Zhu J, Hu X, Shen M, et al. β‑Thujaplicin induces autophagic cell death, apoptosis, and cell cycle arrest through ROS‑mediated Akt and p38/ERK MAPK signaling in human hepatocellular carcinoma. Cell Death Dis. 2019 Mar 15;10(4):255. https://doi.org/10.1038/s41419‑019‑1492‑6</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Лукбанова Е. А., Заикина Е. В., Саяпин Ю. А., Гусаков Е. А., Филиппова С. Ю., Златник Е. Ю. и др. Оценка противоопухолевого эффекта 2‑(6,8‑диметил‑5‑нитро‑4‑хлорхинолин‑2‑ил)‑5,6,7‑трихлор‑1,3‑трополона на подкожных ксенографтах культуры опухолевых клеток А‑549. Альманах клинической медицины. 2021;49(6):396–404. https://doi.org/10.18786/2072‑0505‑2021‑49‑021</mixed-citation><mixed-citation xml:lang="en">Lukyanova EA, Zaikina EV, Sayapin YuA, Gusakov EA, Filippova SYu, Zlatnik EYu, et al. Assessment of an antitumor effect of 2‑(6,8‑dimethyl‑5‑nitro‑4‑chloroquinoline‑2‑yl)‑5,6,7‑trichloro‑1,3‑tropolone in A‑549 tumor cell subcutaneous xenografts. Almanac of Clinical Medicine. 2021;49(6):396–404. https://doi.org/10.18786/2072‑0505‑2021‑49‑021</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Заборовский А. В., Кокорев А. В., Бродовская Е. П., Фирстов С. А., Минаева О. В., Куликов О. А. и др. Направленная доставка доксорубицина с помощью экзогенных биосовместимых нановекторов при экспериментальных неоплазиях. Вестник Мордовского университета. 2017;27(1):93–107. https://doi.org/10.15507/0236‑2910.027.201701.093‑107</mixed-citation><mixed-citation xml:lang="en">Zaborovsky AV, Kokorev AV, Brodovskaya EP, Firstov SA, Minaeva OV, Kulikov OA, et al. Targeted delivery of doxorubicin using exogenous biocompatible nanovectors in experimental neoplasias. Bulletin of the Mordovian University. 2017;27(1):93–107. (In Russ.). https://doi.org/10.15507/0236‑2910.027.201701.093‑107</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ido Y, Muto N, Inada A, Kohroki J, Mano M, Odani T, et al. Induction of apoptosis by hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is mediated through the activation of caspase‑3. Cell Prolif. 1999 Feb;32(1):63–73. https://doi.org/10.1046/j.1365‑2184.1999.3210063.x</mixed-citation><mixed-citation xml:lang="en">Ido Y, Muto N, Inada A, Kohroki J, Mano M, Odani T, et al. Induction of apoptosis by hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is mediated through the activation of caspase‑3. Cell Prolif. 1999 Feb;32(1):63–73. https://doi.org/10.1046/j.1365‑2184.1999.3210063.x</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Chen S‑M, Wang B‑Y, Lee C‑H, Lee H‑T, Li J‑J, Hong G‑C, et al. Hinokitiol up‑regulates miR‑494‑3p to suppress BMI1 expression and inhibits self‑renewal of breast cancer stem/progenitor cells. Oncotarget. 2017 Sep 29;8(44):76057–76068. https://doi.org/10.18632/oncotarget.18648</mixed-citation><mixed-citation xml:lang="en">Chen S‑M, Wang B‑Y, Lee C‑H, Lee H‑T, Li J‑J, Hong G‑C, et al. Hinokitiol up‑regulates miR‑494‑3p to suppress BMI1 expression and inhibits self‑renewal of breast cancer stem/progenitor cells. Oncotarget. 2017 Sep 29;8(44):76057–76068. https://doi.org/10.18632/oncotarget.18648</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lee Y‑S, Choi K‑M, Kim W, Jeon Y‑S, Lee Y‑M, Hong J‑T, et al. Hinokitiol inhibits cell growth through induction of S‑phase arrest and apoptosis in human colon cancer cells and suppresses tumor growth in a mouse xenograft experiment. J Nat Prod. 2013 Dec 27;76(12):2195–2202. https://doi.org/10.1021/np4005135</mixed-citation><mixed-citation xml:lang="en">Lee Y‑S, Choi K‑M, Kim W, Jeon Y‑S, Lee Y‑M, Hong J‑T, et al. Hinokitiol inhibits cell growth through induction of S‑phase arrest and apoptosis in human colon cancer cells and suppresses tumor growth in a mouse xenograft experiment. J Nat Prod. 2013 Dec 27;76(12):2195–2202. https://doi.org/10.1021/np4005135</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Seo JS, Choi YH, Moon JW, Kim HS, Park S‑H. Hinokitiol induces DNA demethylation via DNMT1 and UHRF1 inhibition in colon cancer cells. BMC Cell Biol. 2017 Feb 27;18(1):14. https://doi.org/10.1186/s12860‑017‑0130‑3</mixed-citation><mixed-citation xml:lang="en">Seo JS, Choi YH, Moon JW, Kim HS, Park S‑H. Hinokitiol induces DNA demethylation via DNMT1 and UHRF1 inhibition in colon cancer cells. BMC Cell Biol. 2017 Feb 27;18(1):14. https://doi.org/10.1186/s12860‑017‑0130‑3</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
